Ann: Sept 2022 Quarterly Activities and Cash Flow, page-27

First 27 Last

Share
Profile

Follow
Virgil73

747 Posts.

68

02/11/22

13:54

Post #: 64545870
Share

Originally posted by invertedva: ↑

Just listened to the quarterly results webinar.
Often these things are just a restatement of the announcement, but there were a few new(ish) things I thought worth mentioning:
- the new CFO seems like a solid numbers man. Answered a couple of questions in a clear and concise manner.
- someone asked why the 5000-5500 production forecast was never met. Jordan explained that they could've reached this level given they are not short of land they can drill, but a decision was made to return capital. They seemed to have realigned with the industry standards, whereby a growth-at-all-costs attitude is being replaced by a capital-conservation-and-return philosophy. I am sure this explanation won't please some on here, but it was credible in my opinion.,
- someone asked how much it would cost to test Montney, so as to de-risk it and make it more attractive for someone to acquire. The answer was ~$6 million CAD.
- another titbit, which I'm not sure has been shared before - Toulemene actually made an offer for the Montney lands but this was considered low-ball and rejected by the company. Mark Freeman basically said our land is more likely to be acquired by someone else - Mitsubishi, Canada LNG.
- they are still looking at listing in Canada. Mark Freeman explained that in the small O&G space in Australia, people are more interested in exploration upside than producers like CE1. He noted that some companies in Australia without revenue are valued higher than CE1, which is producing free cash flows and returning capital.
- Someone asked for an update on Leo 4. Jordan was a bit cagey about this. Leo 4 is producing but they don't want to release the data, the main reason being they are bidding on some nearby land, and (my interepretation is) releasing too much data would only bid up prices.

Overall it was a very sober and reassuring presentation.

Expand

I couldn’t get into the webinar. The link just gave me an error.

CE1 Price at posting: 13.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 17 more messages in this thread...

First 27 Last

Add CE1 (ASX) to my watchlist

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $5.122M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Sept 2022 Quarterly Activities and Cash Flow, page-27

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Featured News

Ann: Sept 2022 Quarterly Activities and Cash Flow, page-27

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Featured News